Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$13 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
By the way, drop the conspiracy theories. We're just working through some retail holders that are impatient and want out after going through a roller coaster ride over the past 6 weeks. As soon as these people get out this thing rocks higher.
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$13 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
By the way, drop the conspiracy theories. We're just working through some retail holders that are impatient and want out after going through a roller coaster ride over the past 6 weeks. As soon as these people get out this thing rocks higher.
Close above $0.069 for new closing high since October.
I always look at closing prices instead of the intraday noise.
Again, $14 Million market cap for a company with patent protection on a drug that has had much better results than GDNF which was owned by a company bought out for $250 Million and a drug that the co-founder of Amgen said the following about:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Do the math. $14 Million vs $250 Million. We will see a $100 Million market cap soon.
Dr. Rubinfeld is presenting on 1/8/13. Do you think the data is going to be good?
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$13 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
My money is with the co-founder of Amgen...
I could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them. A partnership with a bigger pharma company that includes a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales.
The $13 Million market cap is a joke. MANF is currently producing significantly better results than GDNF was at this stage of testing when the company that owned it was bought out for $250 Million. I believe AMBS will be at a $100 Million market cap within a year and probably within 6 months.
People who are still doubting this need to ask themselves a few questions:
(1) Why is the co-founder of Amgen wasting his time here? This is a guy with a ridiculously impressive resume. Co-Founder of Amgen, founder of Supergen, invented Amoxicillin.
(2) Why is he presenting along with the CSO, John Commissiong, at a biotech conference known for bringing VC and bigger pharma investors to biotech startups?
(3) Why did the co-Founder of Amgen state that MANF could be the biggest success he has ever seen in his career?
(4) And why did Hermo Pharma, a VC backed and MJFF funded biotech in the same exact field as AMBS, challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Hmmmm.
Again, I'm not going to waste my time listening to some college kids on this board with their $3,000 in life savings trying to bash the stock. Get lost. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have just a little more knowledge about this patent protected drug.
Get ready for the fireworks leading into the January presentation. It's going to be very exciting. I get the feeling this is being accumulated heavily.
Do you think they're going to present bad data to a crowd of Angel Investors, VC Investors, and Big Pharma companies? Do you think the co-founder of Amgen is coming to the stage to present bad data?
Come on people.
$13 Million for a company that has patents on a drug, MANF, that the founder of Amgen thinks" could be the biggest success I have ever seen".
Why is the Co-Founder of Amgen Here?
If you have any doubts this is all you need to ask yourself. We're talking about the freaking co-founder of Amgen, a $67 Billion company. He previously said: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen." And he's presenting on the potential for commercial opportunities of MANF at a conference in January. For doubters: Do you really think they're going to present bad data in front of a conference of VC and angel investors and big pharma companies that are paying $400 to attend?
Then ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$13 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
My money is with the co-founder of Amgen...
A partnership with a bigger pharma company with a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales. I honestly could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them.
People need to ask why the co-founder of Amgen is wasting his time here. Why is he presenting along with the CSO at a biotech conference known for bringing investments to biotech startups? Why did he state that MANF could be the biggest success he has ever seen in his career?
And why did Hermo Pharma challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Hmmmm.
Again, I'm not going to waste my time listening to college kids like you Shillantey on this board with your $3,000 in life savings trying to bash a stock. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have more knowledge.
I could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them. A partnership with a bigger pharma company that includes a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales.
The $13 Million market cap is a joke. MANF is currently producing significantly better results than GDNF was at this stage of testing when the company that owned it was bought out for $250 Million. I believe AMBS will be at a $100 Million market cap within a year and probably within 6 months.
People who are still doubting this need to ask themselves a few questions:
(1) Why is the co-founder of Amgen wasting his time here? This is a guy with a ridiculously impressive resume. Co-Founder of Amgen, founder of Supergen, invented Amoxicillin.
(2) Why is he presenting along with the CSO, John Commissiong, at a biotech conference known for bringing VC and bigger pharma investors to biotech startups?
(3) Why did the co-Founder of Amgen state that MANF could be the biggest success he has ever seen in his career?
(4) And why did Hermo Pharma, a VC backed and MJFF funded biotech in the same exact field as AMBS, challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Hmmmm.
Again, I'm not going to waste my time listening to some college kids on this board with their $3,000 in life savings trying to bash the stock. Get lost. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have just a little more knowledge about this patent protected drug.
Get ready for the fireworks leading into the January presentation. It's going to be very exciting.
A partnership with a bigger pharma company with a license deal will allow them to fund the trials at the partner's expense while giving up a license / royalty on sales. I honestly could care less about the MJFF grants going forward. I agree that the grants are good but this company is setting itself up for a partnership deal with a larger biopharma company. The writing is on the wall. Rubinfeld and the other senior execs from Bayer, Bristol Myers and Pfizer that are on the board will bring a deal to them.
People need to ask why the co-founder of Amgen is wasting his time here. Why is he presenting along with the CSO at a biotech conference known for bringing investments to biotech startups? Why did he state that MANF could be the biggest success he has ever seen in his career?
And why did Hermo Pharma challenge their patents? Why would they say that their patent protection is too broad and causes an undue burden on anyone trying to test for any variant of MANF?
Hmmmm.
Again, I'm not going to waste my time listening to college kids on this board with their $3,000 in life savings trying to bash a stock. I'd rather spend my time listening to guys like the co-founder of Amgen. I know it's crazy but I think they have more knowledge.
Forget about the MJFF Grant guys. Who gives a rats behind about that? We have patent protection that was upheld in court. We have heavyweights on board from Amgen, Bayer, Bristol Myers and Pfizer. They have slightly better connections that will give us a partnership and a licensing deal.
I believe we will get a $25 Million funding partnership with licensing and milestone payments. It's coming with the help of Dr. Rubinfeld, the co-founder of freaking Amgen.
Ask yourself why the co-founder of Amgen is here and said "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen."
Ask yourself why another biotech firm in the same exact field with MJFF grants was compelled to challenge their patents and even stated that the patent protection is so broad that is causes "an undue burden on anyone trying to test MANF and any of its variants".
$13 Million market cap for all of this? Puhlease. This is a friggin freight train heading higher. Anyone trying to flip it for pennies will be very sorry when it runs to $0.40+ and they're left waiting for a dip. It's going to be a $100 Million+ company very soon.
I'll tell you what doesn't smell fishy:
11/6/12:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
12/20/12:
"Thereafter, current Amarantus advisor Dr. Joseph Rubinfeld will provide his views on areas of significant commercial potential for MANF beyond Parkinson's disease."
Who am I going to listen to? College kids with $3,000 to their name thinking they have some sort of power to move a stock or the co-founder of Amgen?
Think bigger. I believe this gets to a $100 Million market cap at least. Ask yourself two simple questions:
(1) Why is the co-founder of Amgen wasting his time on this board, presenting on the commercial opportunities of MANF at some biotech conference and saying MANF "could be one of the biggest successes that I have ever seen" and that "MANF has the commercial potential to become a blockbuster drug."?
(2) Why is another biotech startup working in the same field also with Michael J. Fox Foundation grants challenging their patents? http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
The fact that this company has a $13 Million market cap is a joke. This is being accumulated as we speak. I'm not wasting time listening to some college kids with $3,000 to their name post on this board trying to spread fear. Instead I'm going to listen to the founder of Amgen, the senior execs at Bayer and Bristol Myers and the prior president of the American Medical Association Foundation, all of whom are on this company's board. All of them believe in MANF and MANF has shown much better results than GDNF at this stage of testing, which is when it was purchased for $250 Million.
Give it a few weeks/months and we will be sitting here with a $25 Million partnership deal with additional milestones in place for more funding. Where do you think the stock will be then? I'm gonna go with higher than $0.12. Again, anyone selling now will regret this a lot. Oh and by the way it doesn't matter if they get another grant from MJFF. We're all here for the big partnership from a big pharma company. It's coming.
Let's close above $0.069. I prefer looking at the closing prices and not the candle charts:
http://www.google.com/finance?q=OTC%3AAMBS&ei=qZ3SUOjNPI6OigLmpwE
We have tried to close above there 3 times...twice a month or so ago and one more time 2 days ago. I'm looking for a new closing high above $0.069 to really get things going.
Dr. Rubinfeld Presenting...Wow!
"Thereafter, current Amarantus advisor Dr. Joseph Rubinfeld will provide his views on areas of significant commercial potential for MANF beyond Parkinson's disease."
If anyone doesn't think a partnership deal is in the works they're crazy.
We have the co-founder of Amgen presenting on the commercial potential of MANF beyond PD. He has previously stated that "MANF could be the biggest success I have ever seen". We also have senior execs from Bayer and Bristol Myers as well as a prior president of the American Medical Association Foundation on the board.
We have Hermo Pharma, a MJFF grant recipient and VC backed bio tech firm, that felt compelled to challenge the company's MANF patents because they cause undue burden on anyone trying to test it (i.e., they will have to go through AMBS if they want to) and lost.
We have a drug that has shown significantly better results than another drug that at the same exact stage it is at was bought for $250 Million.
I completely understand why people want to take profits. Do you want to listen to college kids bash the stock like ALL-IN or golong or do you want to listen to the co-founder of Amgen or the president of the American Medical Association Foundation or an executive from Bayer all say how MANF could be a huge success?
The ones that can hold through the ups and downs will make out like bandits with this company.
Wow huge news! Dr. Rubinfeld is presenting on 1/8/12. I highly doubt we don't see big pharma step in soon.
Results coming very soon. Anyone that sold yesterday will be sorry. I completely understand why people want to take profits. However, AMBS is extremely undervalued. Just remember that most investors are impatient and not willing to hold something. Others bash because they have an agenda (e.g., ALL-IN or golong). The ones that can hold through the ups and downs will make out like bandits with this company.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12-13 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Will it close above $0.069? I prefer looking at the closing prices and not the candle charts:
http://www.google.com/finance?q=OTC%3AAMBS&ei=qZ3SUOjNPI6OigLmpwE
Yesterday we closed just shy of new highs. That was the third time it tested the $0.065-$0.069 level. It looks today was a re-charge day before it breaks to new highs.
The President of AMA is on AMBS's Board: WOW!
http://www.ama-assn.org/ama/pub/about-ama/ama-foundation/about-us/the-ama-foundation-board-directors.page?
Owen Garrick - President of the AMA Foundation. This is insane. I didn't realize this.
http://finance.yahoo.com/news/Amarantus-BioSciences-iw-1985257805.html?x=0
""I am pleased to join Amarantus at this exciting time in the Company's development cycle," said Dr. Garrick. "The MANF platform represents an attractive technology with the potential to treat a number of apoptosis-related disorders, beginning with Parkinson's disease. I will be working closely with the team to fully develop the infrastructure to successfully move the MANF programs into clinical development.""
So we have the President of the AMA, the co-founder of Amgen, and senior executives at Bayer and Bristol Myers on the Advisory Board.
Add to this you have patent protection on a protein that has shown far better results than another drug in phase II clinical trials which was owned by a company that received a $250 Million buyout from Amgen. And you have a company in Hermo Pharma, a VC backed biotech with over $700k in grants from MJFF that challenged their patents (and lost) on the grounds that the patents are too broad and cause an undue burden on anyone trying to work on these proteins...
And still people are doubting this company??? Really? You have a bunch of college kids coming on this message board spewing fear and in the meantime you have people on the Advisory Board calling MANF a potential blockbuster drug and potentially one of the biggest successes ever...and you still doubt this company? Who do you trust? College kids who believe charts are talking to them or CEO's of multi billion dollar companies and presidents of the American Medical Association?
Jeez. Get a grip. This thing is worth $13 Million on the open market and yet it should be worth well over $100 Million. The market will realize this soon enough.
Will it close above $0.069? I prefer looking at the closing prices and not the candle charts:
http://www.google.com/finance?q=OTC%3AAMBS&ei=qZ3SUOjNPI6OigLmpwE
Yesterday we close just shy of new highs. That was the third time it tested the $0.065-$0.069 level. It looks today was a re-charge day before it breaks to new highs.
Hermo Pharma for one. They are VC backed and received $700k in grants from the Michael J Fox Foundation. Wonder why they challenged their patents...
http://www.smallcapnetwork.com/Find-a-Cure-For-Parkinsons/s/via/20987/article/view/p/mid/1/id/1/
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
The question is: are you trying to bash again now that you're out of the stock? You past posting history is here for all of us to see
Results coming very soon. Anyone that sold today will be sorry. I understand that people will take profits so the stock is bound to go through bouts of pullbacks. Most investors are impatient and not willing to ride it out for huge gains. And people like golong and ALL-IN will try to bash it in hopes of getting in at cheaper prices.
However, when you compare what some heavy weights are saying about MANF and that AMBS has patent protection on it and those patents were upheld in court, you get a clear sense of much higher prices in the future. The market cap is so tiny on AMBS.
I would pay a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12-13 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Like I said, sellers will regret it soon. I understand if you want to take profits...nothing wrong with that. But keep in mind a few things:
(1) Anything with a 90% similarity (homology) to MANF is considered to have the same characteristics that the AMBS patents cover. So if they alter GDNF during phase II trials and it has a similar structure then they have to talk to AMBS about licensing it. If anyone wants to alter CDNF or MANF during testing they have to talk to AMBS about licensing it. There is a reason Hermo Pharma challenged their patents and why the co-founder of Amgen said "MANF could be the biggest success I have ever seen."
(2) Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing. AMBS is only valued at $12 Million
You can try to get cute with flipping your shares but the moment a JV is announced you're not going to be able to get in. There is a reason the co-founder of Amgen is here. There is a reason senior executives of Bayer and Bristol Myers are here. They are not going to waste their time with something that they haven't done the research on.
Results coming very soon. Anyone that sold today will be sorry. I completely understand why people want to take profits. However, AMBS is extremely undervalued. Just remember that most investors are impatient and not willing to hold something. Others bash because they have an agenda (e.g., ALL-IN or golong). The ones that can hold through the ups and downs will make out like bandits with this company.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $11-12 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Results coming very soon. Anyone that sold today will be sorry. I bought another 300k shs today. Remember that most investors are impatient and not willing to hold something. Others bash because they have an agenda (e.g., ALL-IN or golong). The ones that can hold through the ups and downs will make out like bandits.
Ask yourself 2 simple questions:
(1) Why is the co-founder of Amgen saying MANF "could be one of the biggest successes that I have ever seen."? This is a 79 year old man that has seen a lot of things in his career.
(2) Why did Hermo Pharma, a MJFF grant recipient and VC backed, feel compelled to challenge the company's MANF patents?
MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $11-12 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Results coming very soon. Anyone that sold today will be sorry. I bought another 300k shs today.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories because there is no conspiracy going on.
I would pay a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $11-12 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories because there is no conspiracy going on.
I would pay a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $11-12 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
In their own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Wow this is strong. I managed to pick up another 200k shares at $0.05...Tried at $0.047 but no dice.
ALL-IN - You're one of the best traders I've seen...after the fact! LOL
TAGG had a 1 week rally and it was over. AMBS is up about 8 fold from its base in October and it is holding it's ground. Nice try but that's a horrible parallel.
We all appreciate your worry for our well-being. You obviously have no desire to try to get the stock lower so you can buy. None of us can tell that.
In the meantime I will pay a little more attention to what the co-founder of Amgen said about MANF:
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
Whomever is debating buying this company please don't listen to the negative posts without understand they're most likely hoping it will drop so they can get more. They have their own agendas.
I would pay just a little more attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $14 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $13-14 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
I would pay attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12-13 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
Awesome article: http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
This explains all you need to know about AMBS. It has patent protection on MANF which was upheld by Hermo Pharma who is quoted in the above article as saying that their patent protection causes an undue burden on anyone trying to work on MANF. Think about how powerful of a statement that is.
Then look at their valuation: $13 Million for something that has had much better results than GDNF which was owned by a company that was bought out for $250 Million by Amgen while GDNF was in the same stage of testing as MANF: pre-clinical trials. GDNF was halted due to poor delivery methods but it is currently revived in phase II trials because delivery methods have been vastly improved over the past 10 years.
Then look at the statement by the CO FOUNDER OF AMGEN: "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug." This is a 79 year old man that started up Amgen, that invented Amoxicillin, and that founded Supergen.
Ask yourself:
(1) Should this be worth $13 Million when it is producing better results than another drug that received a $250 Million buyout?
(2) Should this be worth $13 Million when junk penny stocks like MJNA, TAGG, SPNG, GZFX at one point had $100-$175 Million market caps?
There is a reason why Hermo Pharma contested their patents and why the co-Founder of Amgen believes it could be the biggest success he has ever seen.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
I would pay attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12-13 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
Market cap is TINY at $13 Million.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $9 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen. A funding deal is in the works and when it happens you can kiss these prices goodbye.
AMBS Market cap = $14 Million
TAGG peaked at $100 Million
MJNA at $100 Million
SPNG (Spongetech) at $170 Million
GZFX (GameznFlix) at $100 Million
Which one has/had more promise?
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
Dr. Rubinfeld is one of the four original co-founders of Amgen . Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb . Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until he co-founded SuperGen in 1991, and served as its President & CEO through 2003.
Market cap is TINY at $13 Million.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $9 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
These are his own words:
"Their patent covers all sequences with 90% homology to MANF (182 amino acid protein --> variation in 18 amino acid residues allowed, 20 options for each position --> you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."
Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
AMBS is only worth $13-14 Million right now.
Versus $250 Million.
Do the math.
And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
I would pay attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12-13 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.
The market cap is so tiny on AMBS. That's all that matters and it is worth repeating. People will sell for a variety of reasons...most likely because they either had a great entry point or a much higher entry point and just want to get out. Most investors are impatient. I would drop any conspiracy theories.
I would pay attention to the comments from the co-founder of Amgen (i.e., "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen.") and think to yourself why Hermo Pharma felt compelled to challenge their MANF patents. MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.
http://seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s
AMBS is only worth $12-13 Million right now.
Versus $250 Million.
Do the math. Listen to people that know the science like Dr. Rubinfeld and the dozens of other scientists that have worked on MANF over the past 10 years (just google MANF if you don't believe me). AMBS has patent protection on MANF and anything that has a 90% homology (i.e., similarity) to MANF. These proteins can be modified to treat the diseases better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents.